Prof. Yongsheng Li 李咏生
Chief Physician, Professor
Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Precision diagnosis and treatment of digestive, respiratory, urogenital, lymphoma, bone and soft tissue tumors. Expertise in molecular targeted therapy, tumor metabolism, immunotherapy, palliative care, and adverse event management.
Dr. Li holds a medical doctorate from Huazhong University of Science and Technology and completed postdoctoral training at Harvard Medical School. As Director of the Department of Medical Oncology at Chongqing University Cancer Hospital, Dr. Li focuses on lipid metabolism and tumor immunity. Research interests include tumor immunometabolism, microenvironment, and targeted therapy. Dr. Li has led 16 research projects and published over 70 articles.
Professional roles
- Deputy Secretary-General and Leader of Immunometabolism Group, Tumor Metabolism Committee, China Anti-Cancer Association
- Standing Committee Member, Tumor and Microecology Committee, China Anti-Cancer Association
- Chair, Metabolic Immunology Committee, Chongqing Immunological Society
- Associate Editor, Frontiers in Immunology
Name order: in Chinese the family name comes first (Li Yongsheng). Papers usually list the name as Yongsheng Li or Li Y.
Selected publications
99 papers on PubMed matched by name and affiliation; 52 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Biomed, 2026 (senior author): Alistipes-derived monomethyl branched-chain fatty acid iso-15:0 suppresses hepatocellular carcinoma progression by inhibiting Gβγ/PI3K/AKT signaling. PubMed 42873452
- Biochim Biophys Acta Rev Cancer, 2026 (senior author): Targeting cholesterol metabolism: a core regulator of tumor-associated macrophage plasticity and immunotherapy response. PubMed 41962811
- Cancer Med, 2026 (first author): Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α-Positive Advanced Ovarian Cancer. PubMed 42165281
- Curr Med Chem, 2026 (senior author): A Global Bibliometric and Visualized Analysis of Proteolysis Targeting Chimeras from 2015 to 2024. PubMed 41863172
- Mol Biomed, 2025 (senior author): CD39 and CD73: biological functions, diseases and therapy. PubMed 41188606
- Cancers (Basel), 2025 (senior author): The Role of WWOX in Cancer Progression: Mechanisms and Therapeutic Potential. PubMed 41228229
- Immunotargets Ther, 2025 (senior author): Regulation of Histone Acetylation During Inflammation Resolution. PubMed 41146849
- MedComm (2020), 2025 (senior author): Cholesterol 25-Hydroxylase Enhances Myeloid-Derived Suppressor Cell (MDSC) Immunosuppression via the Stimulator of Interferon Genes (STING)-Tank-Binding Kinase 1 (TBK1)-Receptor-Interacting Protein Kinase 3 (RIPK3) Pathway in Colorectal Cancer. PubMed 41020041
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion